| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | Sacituzumab Govitecan + Pembrolizumab - (EVOKE-02) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Relapsed/Refractory Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Head and neck squamous cell carcinoma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Hepcludex (Bulevirtide) - (MYR204) | Hepatitis delta virus (HDV) | Phase 2b | Trial Completed | Subcutaneous | Antiviral |
| Gilead Sciences Inc. | Magrolimab in Combination With Nab-Paclitaxel | Metastatic triple-negative breast cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Axicabtagene Ciloleucel (Axi-Cel) with Rituximab - (ZUMA-14) | Refractory Large B-cell Lymphoma (R-LBCL) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Solid tumors | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Colorectal cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |